Kelyrab-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with functional dyspepsia and gastroparesis. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing effective relief from acid-related disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing efficacy and improving patient compliance by reducing dosing frequency. Kelyrab-L Capsule SR is indicated for patients requiring combined prokinetic and acid-suppressive therapy to address complex upper gastrointestinal conditions. It should be administered under medical supervision, with caution in patients with known hypersensitivity to either component, and used judiciously in individuals with hepatic or renal impairment. Monitoring for potential adverse effects such as extrapyramidal symptoms, headache, or gastrointestinal disturbances is recommended during therapy.